Table 1. Patient demographics

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | Control Group1 | LNG-IUS Group | P value2 |
| Age (years) | 64.1 ± 8.7 | 57.6 ± 5.4 | 0.06 |
| BMI (kg/m2) | 28.2 ± 4.4 | 26.4 ± 3.7 | 0.35 |
| Time since the Menopause (years) | 13.3 ± 3.4 | 7.0 ± 1.5 | 0.11 |
| Breast Cancer Stage | T1 N0 M0 (n=1)  T1 N0 MX (n=6)  T2 N0 MX (n=1)  T2 NX MX (n=1)  T2 N1 M0 (n=1) | T1 N0 M0 (n=3)  T1 N0 MX (n=4)  T1 N1 MX (n=1)  T2 N0 MX (n=1)  T4 N1 M0 (n=1) | N/A |
| TMX Duration (days)3 | 47.1 ± 22.8 | 44.0 ± 27.3 | 0.70 |

1. Data are mean ± SE
2. P values were calculated using Student’s Unpaired *t*-test
3. TMX duration is the time of exposure to tamoxifen before insertion of the levonorgestrel-intrauterine device (LNG-IUS)